Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plantamajoside is a phenylethanoid glycoside and hydroxycinnamic acid derivative found in several plants including Plantago asiatica and Rehmannia glutinosa. It exhibits diverse biological activities such as antioxidant, anti-inflammatory, antibacterial (notably against MRSA via inhibition of sortase A), anti-tumor (including potentiation of metformin-induced apoptosis in liver cancer cells), neuroprotective effects (promoting recovery after spinal cord injury in animal models), and protective effects on pancreatic β-cells in type 2 diabetes mellitus by reducing endoplasmic reticulum stress through upregulation of DNAJC1. Mechanistically, it acts as an inhibitor of the NF-κB pathway and MAPK signaling pathways; it also suppresses Akt/GSK3β signaling. Its antibacterial action is attributed to reversible inhibition of Staphylococcus aureus sortase A (SrtA), thereby reducing bacterial adhesion and biofilm formation[1][2][4][5][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on plantamajoside.